To include your compound in the COVID-19 Resource Center, submit it here.

MultiStem: Interim Phase I data

Interim data from 18 patients in the single infusion arm of an ongoing, open-label, dose-escalation Phase I study showed that all doses of MultiStem were well

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE